NBI-42902

NBI-42902 Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: Shanghai Witofly Chemical Co.,Ltd  
Tel:
Email: sales@witofly.com
Company Name: Cckinase, Inc.  
Tel: +1 (732)236-3202
Email: sales@cckinase.com
Company Name: Shanghai Dexuan Pharmaceutical Technology Co., Ltd  
Tel: dexuanyiyao@126.com
Email: dexuanyiyao@126.com
Company Name: Wuhan Topule  
Tel: +86-02787215551 19945035818
Email: 2936752263@qq.com

NBI-42902 manufacturers

  • NBI-42902
  • NBI-42902 pictures
  • $1710.00
  • 2026-05-11
  • CAS:352290-60-9
  • Purity:
  • Supply Ability: 10g
NBI-42902 Basic information
Product Name:NBI-42902
Synonyms:NBI-42902;3-[(2R)-2-Amino-2-phenylethyl]-1-[(2,6-difluorophenyl)methyl]-5-(2-fluoro-3-methoxyphenyl)-6-methyl-2,4(1H,3H)-pyrimidinedione;CS-1113;NBI-42902;NBI 42902;2,4(1H,3H)-Pyrimidinedione, 3-[(2R)-2-amino-2-phenylethyl]-1-[(2,6-difluorophenyl)methyl]-5-(2-fluoro-3-methoxyphenyl)-6-methyl-;(R)-3-(2-amino-2-phenylethyl)-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)-6-methylpyrimidine-2,4(1H,3H)-dione
CAS:352290-60-9
MF:C27H24F3N3O3
MW:495.49
EINECS:
Product Categories:
Mol File:352290-60-9.mol
NBI-42902 Structure
NBI-42902 Chemical Properties
form Solid
color White to off-white
Safety Information
MSDS Information
NBI-42902 Usage And Synthesis
UsesNBI-42902 is an orally active, potent functional and competitive antagonist of GnRH receptor with an IC50 value of 0.79 nM, a Ki value of 0.56 nM, respectively. NBI-42902 inhibits GnRH-stimulated inositol phosphate (IP) accumulation, Ca2+ flux, and ERK1/2 activation. NBI-42902 inhibits serum luteinizing hormone (LH) in castrated male macaques. NBI-42902 can be used for research on sex-hormone-related diseases[1].
in vivo

NBI-42902 (10-100 mg/kg, p.o. or i.v. ) inhibits serum LH levels significantly in castrated macaques[1].

Animal Model:Castrated macaques[1]
Dosage:10, 40, 100 mg/kg
Administration:Oral administration (p.o.)
Result:Inhibited serum LH with dose dependent.
Inhibited serum LH achieved maximum suppression, that was 62-68% of pretreatment baseline, at 4-8 h after administration.
Exhibited no suppression of LH levels after 24 h treated with 10 or 40 mg/kg, but remained suppression at 100 mg/kg.
Animal Model:Castrated macaques[1]
Dosage:10 mg/kg
Administration:Intravenous injection (i.v.)
Result:Inhibited serum LH achieved maximum suppression was 62-68% of pretreatment baseline between 4-8 h after administration, but exhibited no suppression after 24 h.
References[1] Struthers RS, et al. Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902. Endocrinology. 2007 Feb;148(2):857-67. DOI:10.1210/en.2006-1213
NBI-42902 Preparation Products And Raw materials
Tag:NBI-42902(352290-60-9) Related Product Information
Carbamic acid, N-[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]-, 1,1-dimethylethyl ester 1150560-42-1 2,4(1H,3H)-Pyrimidinedione, 3-[(2S)-2-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-6-methyl- elagolix NBI-42902 Butanoic acid, 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]hydroxyamino]-